Skip to main content
. 2019 Mar 28;57(1):145–153. doi: 10.1080/13880209.2019.1585460

Figure 1.

Figure 1.

Study flow chart. Fifteen of the 16 subjects screened were randomized in the study with 15 in the PHYLLPRO™ and placebo group, crossed over and included as the per-protocol final analysis. Subjects who received PHYLLPRO™ during Arm 1 received placebo during Arm 2. Subjects who received placebo during Arm 1 received PHYLLPRO™ during Arm 2.